GlassScriptPhysician profile
Shannon M Morgans
NPI 1700042660
$7,977.95
in general payments reported to CMS, 2019-2025
25 companies · $893 in 2025
The $893 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $1,252 · 2021: $1,626 · 2022: $1,365 · 2023: $766 · 2024: $862 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,532.24 | 2019-2025 | Total30, Dailies, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $1,185.97 | 2019-2024 | |
| Allergan, INC. | $731.58 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $576.32 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $520.46 | 2022-2025 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $518.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $455.96 | 2019-2023 | |
| Optovue, INC. | $246.81 | 2019 | |
| The Cameron-Ehlen Group, INC. | $241.13 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $236.12 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $210.36 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $208.15 | 2021-2022 | |
| Glaukos Corporation | $195.28 | 2025 | Photrexa Viscous and Photrexa |
| Dompe US, INC. | $182.93 | 2021-2025 | Oxervate |
| Shire North American Group INC | $181.91 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $171.52 | 2019-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.18 | 2019-2021 | |
| Optos, INC. | $94.64 | 2022 | |
| Mallinckrodt Hospital Products INC. | $92.99 | 2020 | |
| Lombart Brothers, INC. | $80.98 | 2019-2024 | Opd-III |
| Visionix USA, INC | $64.18 | 2022 | |
| Eyevance Pharmaceuticals LLC | $49.40 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $38.86 | 2020 | |
| Harrow Eye, LLC | $37.31 | 2024-2025 | Vevye |
| Spark Therapeutics, INC. | $17.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Morgans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.